Vascular Anomalies - Pipeline Insight, 2024

This “Vascular Anomalies- Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Vascular Anomalies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vascular Anomalies: Understanding

Vascular Anomalies: Overview

Vascular anomalies encompass a broad spectrum of disorders involving the blood vessels. They can be broadly categorized into vascular tumors, such as hemangiomas, and vascular malformations, which include conditions like arteriovenous malformations, lymphatic malformations, and capillary malformations. These anomalies can affect any part of the body and vary significantly in their presentation, from small, harmless birthmarks to life-threatening complications. Their classification and understanding have improved over the years due to advancements in imaging and molecular biology. The signs and symptoms of vascular anomalies depend on their type, location, and size. Hemangiomas typically appear as red or blue nodules on the skin, often growing rapidly during the first year of life before gradually involuting. Vascular malformations, on the other hand, tend to grow proportionally with the child and may not be noticeable until later in life. Symptoms can range from cosmetic concerns and local pain to more severe manifestations like bleeding, ulceration, or compression of nearby structures, leading to functional impairments. For instance, arteriovenous malformations can cause significant pain, swelling, and even high-output heart failure due to abnormal blood flow patterns.

The causes of vascular anomalies are often genetic, involving mutations that affect vascular development and growth. For example, mutations in the RAS/MAPK pathway have been implicated in some hemangiomas, while other anomalies are linked to genetic conditions like hereditary hemorrhagic telangiectasia. The pathophysiology of these anomalies involves aberrant signaling pathways that regulate angiogenesis and vascular remodeling, leading to abnormal vessel formation and growth. Hemangiomas are thought to arise from a clonal expansion of endothelial cells, whereas vascular malformations result from errors in vascular morphogenesis during embryonic development.

Diagnosis of vascular anomalies involves a combination of clinical evaluation, imaging studies, and sometimes genetic testing. Physical examination can provide initial clues, but imaging techniques such as ultrasound, MRI, and CT scans are crucial for determining the extent and nature of the anomaly. These imaging modalities help in differentiating between high-flow and low-flow lesions, guiding further management. In some cases, biopsy and histopathological examination are necessary to distinguish between different types of vascular tumors and malformations. Genetic testing may be employed to identify specific mutations associated with familial vascular anomaly syndromes.

Treatment for vascular anomalies depends on their type, location, symptoms, and potential complications. Hemangiomas, for example, may be managed with observation, beta-blockers like propranolol, or corticosteroids in more severe cases. Vascular malformations often require a multidisciplinary approach involving interventional radiology, surgery, and sometimes sclerotherapy, where a sclerosant agent is injected to obliterate the abnormal vessels. Laser therapy is another option for superficial capillary malformations. Advances in molecular biology have led to targeted therapies that inhibit specific pathways involved in the growth of these anomalies, offering new hope for effective management. The goal of treatment is to control symptoms, prevent complications, and improve the quality of life for affected individuals.

"Vascular Anomalies- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Anomalies pipeline landscape is provided which includes the disease overview and Vascular Anomalies treatment guidelines. The assessment part of the report embraces, in depth Vascular Anomalies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Anomalies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Anomalies R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Anomalies.

Vascular Anomalies Emerging Drugs Chapters

This segment of the Vascular Anomalies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Anomalies Emerging Drugs

KP-001: Kaken Pharmaceutical Co., Ltd

KP-001 (ART-001) is an orally-available PI3Kα inhibitor that is currently under development for slow-flow vascular malformations. ART-001 potently and selectively inhibited PI3Kα and exhibits “antitumor effect” and “anti-angiogenesis effect” in in vitro and in vivo preclinical models. In addition, the excellent pharmacokinetic and safety profile with the new formulation was demonstrated in the Phase I study in healthy adults, which had been presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Annual Meeting. ART-001 is being developed for refractory intractable vascular malformations, diseases with high unmet medical need without no effective treatment. ART-001 was originally developed by ARTham Therapeutics Inc. ARTham Therapeutics Inc. was acquired by Kaken Pharmaceutical Co. LTD. Currently, the drug is in Phase III stage of its development for the treatment of vascular anomalies.

Vascular Anomalies: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Anomalies drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vascular Anomalies

• There are approx. 3+ key companies which are developing the therapies for Vascular Anomalies. The companies which have their Vascular Anomalies drug candidates in the most advanced stage, i.e. phase III include, Kaken Pharmaceutical Co., Ltd

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Vascular Anomalies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Anomalies: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Anomalies therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Anomalies drugs.

Vascular Anomalies Report Insights

• Vascular Anomalies Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vascular Anomalies Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vascular Anomalies drugs?
• How many Vascular Anomalies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Anomalies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vascular Anomalies therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Anomalies and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kaken Pharmaceutical Co., Ltd
• Nobelpharma Co., Ltd.
• Palvella Therapeutics, Inc.

Key Products

• KP-001
• NPC-12G
• QTORINTM rapamycin 3.9%

This product will be delivered within 2 business days.